Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-8

The figure certainly is fact, but I note it is all grants. Nothing wrong with that as the funds must be managed well and the R&D costs seem quite low for a tech company doing trials. So well done to management on this.

I see the total grants of 15.5m is now at 3.25m. Anyone have any idea of further grants once all that is used? Perhaps a hard question I know that even management are unsure of. But have they received grants before these ones?

The FDA submission is a ways off yet, with quite a bit yet to do (although I see management are confident of achieving a 'streamlined' application process. Not that it is often achieved with the FDA's fickle procedures.)